Loading...

QURE UNIQURE NV US FDA Inspections 8-K Filing

NQR

QR

UNIQURE NV

(QURE)

2026 8-K

Financial Results Update

Regulatory Submission Planned

Financial Results Update

Corporate Presentation Update

FDA Meeting Scheduled

Regulatory Update

Financial Update

Regulatory Update

Public Offering Announcement

Loan Amendment Details

Clinical Trial Update

Equity Offerings

Financial Statements

Rights Offerings

Pre-Market Approval

Financial Statements

CEO Agreement Update

Financial Results

Public Offering

Clinical Trial Update

Financial Results

Clinical Trial Update

FDA Designation

Clinical Trial Update

Financial Results Announcement

Sale of Lexington Facility ...

Clinical Trial Updates

Asset Purchase Agreement

Annual Meeting Results

FDA Designation for AMT-130...

Financial Results Announcement

Departure of Directors

Financial Results Announcement

Clinical Trial Updates

Share Incentive Plan Amendment

Earnings Reports

Costs Associated with Exit ...

Earnings Reports

Annual General Meeting

Royalty Purchase Agreement

Financial Results Announcement

Retirement of Chief Regulat...

Financial Results Announcement

Licensing Agreement

External Links:

On April 30, 2026, uniQure N.V. announced it held a pre-submission meeting with the UK’s regulatory agency for its gene therapy AMT-130 for Huntington’s disease and plans to submit its Marketing Authorization Application in Q3 2026.

AI Assistant

UNIQURE NV

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.